Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malaria

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 62 articles:
HTML format
Text format



Single Articles


    October 2017
  1. SHIRATSUCHI T, Rai U, Kaneko I, Zhang M, et al
    A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII.
    Vaccine. 2017 Oct 28. pii: S0264-410X(17)31474.
    PubMed     Text format     Abstract available


  2. PERRAUT R, Varela ML, Joos C, Diouf B, et al
    Association of antibodies to Plasmodium falciparum merozoite surface protein-4 with protection against clinical malaria.
    Vaccine. 2017 Oct 14. pii: S0264-410X(17)31391.
    PubMed     Text format     Abstract available


    September 2017
  3. SIRIMA SB, Durier C, Kara L, Houard S, et al
    Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel(R) in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Vaccine. 2017 Sep 22. pii: S0264-410X(17)31247.
    PubMed     Text format     Abstract available


  4. VENKATRAMAN N, Anagnostou N, Bliss C, Bowyer G, et al
    Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M.
    Vaccine. 2017 Sep 20. pii: S0264-410X(17)31248.
    PubMed     Text format     Abstract available


    June 2017
  5. GENITO CJ, Beck Z, Phares TW, Kalle F, et al
    Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Vaccine. 2017 Jun 5. pii: S0264-410X(17)30729.
    PubMed     Text format     Abstract available


    May 2017
  6. SINGH SK, Thrane S, Janitzek CM, Nielsen MA, et al
    Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Vaccine. 2017 May 31. pii: S0264-410X(17)30690.
    PubMed     Text format     Abstract available


  7. GBEDANDE K, Fievet N, Viwami F, Ezinmegnon S, et al
    Clinical development of a VAR2CSA-based placental malaria vaccine PAMVAC: Quantifying vaccine antigen-specific memory B & T cell activity in Beninese primigravidae.
    Vaccine. 2017 May 17. pii: S0264-410X(17)30635.
    PubMed     Text format     Abstract available


  8. FONSECA JA, McCaffery JN, Kashentseva E, Singh B, et al
    A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.
    Vaccine. 2017 May 5. pii: S0264-410X(17)30554.
    PubMed     Text format     Abstract available


  9. LI X, Huang J, Kawamura A, Funakoshi R, et al
    Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect.
    Vaccine. 2017 May 5. pii: S0264-410X(17)30578.
    PubMed     Text format     Abstract available


    April 2017
  10. CHATTOPADHYAY R, Pratt D
    Role of controlled human malaria infection (CHMI) in malaria vaccine development: A U.S. food & drug administration (FDA) perspective.
    Vaccine. 2017 Apr 18. pii: S0264-410X(17)30406.
    PubMed     Text format    



  11. Malaria vaccine: WHO position paper, January 2016 - Recommendations.
    Vaccine. 2017 Apr 3. pii: S0264-410X(16)30982.
    PubMed     Text format     Abstract available


    March 2017
  12. LUO K, Zavala F, Gordy J, Zhang H, et al
    Extended protection capabilities of an immature dendritic-cell targeting malaria sporozoite vaccine.
    Vaccine. 2017 Mar 22. pii: S0264-410X(17)30369.
    PubMed     Text format     Abstract available


  13. FORD T, Wenden C, Mbekeani A, Dally L, et al
    Cryopreservation-related loss of antigen-specific IFNgamma producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy.
    Vaccine. 2017 Mar 9. pii: S0264-410X(17)30241.
    PubMed     Text format     Abstract available


    January 2017
  14. ANDERSSON AC, Resende M, Salanti A, Nielsen MA, et al
    Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen.
    Vaccine. 2017 Jan 25. pii: S0264-410X(17)30033.
    PubMed     Text format     Abstract available


  15. KANOI BN, Takashima E, Morita M, White MT, et al
    Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda.
    Vaccine. 2017 Jan 12. pii: S0264-410X(17)30003.
    PubMed     Text format     Abstract available


  16. MILLIGAN P, Flach C, Theisen M
    Efficacy of the GMZ2 malaria vaccine in African children.
    Vaccine. 2017;35:202.
    PubMed     Text format    


  17. EJIGU DA
    When should a time at risk start in efficacy malaria vaccine trials?
    Vaccine. 2017;35:201.
    PubMed     Text format    


    December 2016
  18. PEHRSON C, Heno KK, Adams Y, Resende M, et al
    Comparison of functional assays used in the clinical development of a placental malaria vaccine.
    Vaccine. 2016 Dec 21. pii: S0264-410X(16)31235.
    PubMed     Text format     Abstract available


    November 2016
  19. DATTA D, Bansal GP, Gerloff DL, Ellefsen B, et al
    Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.
    Vaccine. 2016 Nov 29. pii: S0264-410X(16)31143.
    PubMed     Text format     Abstract available


  20. GALACTIONOVA K, Tediosi F, Camponovo F, Smith TA, et al
    Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa.
    Vaccine. 2016 Nov 24. pii: S0264-410X(16)31103.
    PubMed     Text format     Abstract available


    October 2016
  21. BRICKLEY EB, Coulibaly M, Gabriel EE, Healy SA, et al
    Utilizing direct skin feeding assays for development of vaccines that interrupt malaria transmission: A systematic review of methods and case study.
    Vaccine. 2016 Oct 24. pii: S0264-410X(16)30945.
    PubMed     Text format     Abstract available


    September 2016
  22. SPEARMAN P, Mulligan M, Anderson EJ, Shane AL, et al
    A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.
    Vaccine. 2016 Sep 30. pii: S0264-410X(16)30855.
    PubMed     Text format     Abstract available


  23. NTEGE EH, Arisue N, Ito D, Hasegawa T, et al
    Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
    Vaccine. 2016 Sep 28. pii: S0264-410X(16)30841.
    PubMed     Text format     Abstract available


    August 2016
  24. LI X, Huang J, Zhang M, Funakoshi R, et al
    Human CD8+ T cells mediate protective immunity induced by a human malaria vaccine in human immune system mice.
    Vaccine. 2016 Aug 5. pii: S0264-410X(16)30663.
    PubMed     Text format     Abstract available


    July 2016
  25. SIRIMA SB, Mordmuller B, Milligan P, Ngoa UA, et al
    A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.
    Vaccine. 2016 Jul 28. pii: S0264-410X(16)30625.
    PubMed     Text format     Abstract available


  26. PARSONS E, Epstein J, Sedegah M, Villasante E, et al
    Decrease in circulating CD25hiFoxp3+ regulatory T cells following vaccination with the candidate malaria vaccine RTS,S.
    Vaccine. 2016 Jul 18. pii: S0264-410X(16)30581.
    PubMed     Text format     Abstract available


    May 2016
  27. BLAGBOROUGH AM, Musiychuk K, Bi H, Jones RM, et al
    Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax.
    Vaccine. 2016 May 10. pii: S0264-410X(16)30290.
    PubMed     Text format     Abstract available


    March 2016
  28. BALDWIN SL, Roeffen W, Singh SK, Tiendrebeogo RW, et al
    Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen.
    Vaccine. 2016 Mar 16. pii: S0264-410X(16)00327.
    PubMed     Text format     Abstract available


  29. BIRKETT AJ
    Status of vaccine research and development of vaccines for malaria prepared for WHO PD-VAC.
    Vaccine. 2016 Mar 15. pii: S0264-410X(16)00294.
    PubMed     Text format     Abstract available


    February 2016
  30. GONCALVES BP, Prevots DR, Kabyemela E, Fried M, et al
    Preparing for future efficacy trials of severe malaria vaccines.
    Vaccine. 2016 Feb 25. pii: S0264-410X(16)00234.
    PubMed     Text format     Abstract available


    December 2015
  31. KPANAKE L, Sorum PC, Mullet E
    The potential acceptability of infant vaccination against malaria: A mapping of parental positions in Togo.
    Vaccine. 2015 Dec 17. pii: S0264-410X(15)01780.
    PubMed     Text format     Abstract available


    November 2015
  32. KANGOYE DT, Mensah VA, Murungi LM, Nkumama I, et al
    Dynamics and role of antibodies to Plasmodium falciparum merozoite antigens in children living in two settings with differing malaria transmission intensity.
    Vaccine. 2015 Nov 2. pii: S0264-410X(15)01473.
    PubMed     Text format     Abstract available


    October 2015
  33. SAUERWEIN RW, Richie TL
    Malaria vaccines getting close to clinical reality.
    Vaccine. 2015 Oct 27. pii: S0264-410X(15)01548.
    PubMed     Text format    


  34. LAPKE N, Tartz S, Lee KH, Jacobs T, et al
    The application of anti-Toso antibody enhances CD8 T cell responses in experimental malaria vaccination and disease.
    Vaccine. 2015 Oct 24. pii: S0264-410X(15)01494.
    PubMed     Text format     Abstract available


  35. EWER KJ, Sierra-Davidson K, Salman AM, Illingworth JJ, et al
    Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".
    Vaccine. 2015 Oct 14. pii: S0264-410X(15)01384.
    PubMed     Text format     Abstract available


  36. WHITE MT, Verity R, Churcher TS, Ghani AC, et al
    Vaccine approaches to malaria control and elimination: Insights from mathematical models.
    Vaccine. 2015 Oct 14. pii: S0264-410X(15)01389.
    PubMed     Text format     Abstract available


  37. OUATTARA A, Barry AE, Dutta S, Remarque EJ, et al
    Designing malaria vaccines to circumvent antigen variability.
    Vaccine. 2015 Oct 13. pii: S0264-410X(15)01414.
    PubMed     Text format     Abstract available


  38. NAHRENDORF W, Scholzen A, Sauerwein RW, Langhorne J, et al
    Cross-stage immunity for malaria vaccine development.
    Vaccine. 2015 Oct 12. pii: S0264-410X(15)01388.
    PubMed     Text format     Abstract available


  39. PATARROYO ME, Patarroyo MA, Pabon L, Curtidor H, et al
    Immune protection-inducing protein structures (IMPIPS) against malaria: the weapons needed for beating Odysseus.
    Vaccine. 2015 Oct 12. pii: S0264-410X(15)01412.
    PubMed     Text format     Abstract available


  40. BIRKETT AJ
    Building an effective malaria vaccine pipeline to address global needs.
    Vaccine. 2015 Oct 12. pii: S0264-410X(15)01415.
    PubMed     Text format     Abstract available


  41. RICHIE TL, Billingsley PF, Sim BK, Epstein JE, et al
    Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines.
    Vaccine. 2015 Oct 12. pii: S0264-410X(15)01386.
    PubMed     Text format     Abstract available


  42. FRIED M, Duffy PE
    Designing a VAR2CSA-based vaccine to prevent placental malaria.
    Vaccine. 2015 Oct 12. pii: S0264-410X(15)01422.
    PubMed     Text format     Abstract available


  43. BIJKER EM, Borrmann S, Kappe SH, Mordmuller B, et al
    Novel approaches to whole sporozoite vaccination against malaria.
    Vaccine. 2015 Oct 12. pii: S0264-410X(15)01385.
    PubMed     Text format     Abstract available


  44. DRAPER SJ, Angov E, Horii T, Miller LH, et al
    Recent advances in recombinant protein-based malaria vaccines.
    Vaccine. 2015 Oct 9. pii: S0264-410X(15)01383.
    PubMed     Text format     Abstract available


  45. WU Y, Narum DL, Fleury S, Jennings G, et al
    Particle-based platforms for malaria vaccines.
    Vaccine. 2015 Oct 9. pii: S0264-410X(15)01387.
    PubMed     Text format     Abstract available


  46. TENEZA-MORA N, Lumsden J, Villasante E
    A malaria vaccine for travelers and military personnel: Requirements and top candidates.
    Vaccine. 2015 Oct 9. pii: S0264-410X(15)01413.
    PubMed     Text format     Abstract available


    September 2015
  47. VIEBIG NK, D'Alessio F, Draper SJ, Sim BK, et al
    Workshop report: Malaria vaccine development in Europe-preparing for the future.
    Vaccine. 2015 Sep 30. pii: S0264-410X(15)01350.
    PubMed     Text format     Abstract available


  48. KASLOW DC, Biernaux S
    RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap.
    Vaccine. 2015 Sep 29. pii: S0264-410X(15)01337.
    PubMed     Text format     Abstract available


  49. DAVIES DH, Duffy P, Bodmer JL, Felgner PL, et al
    Large screen approaches to identify novel malaria vaccine candidates.
    Vaccine. 2015 Sep 28. pii: S0264-410X(15)01335.
    PubMed     Text format     Abstract available


  50. MUELLER I, Shakri AR, Chitnis CE
    Development of vaccines for Plasmodium vivax malaria.
    Vaccine. 2015 Sep 28. pii: S0264-410X(15)01336.
    PubMed     Text format     Abstract available


  51. STANISIC DI, Good MF
    Whole organism blood stage vaccines against malaria.
    Vaccine. 2015 Sep 28. pii: S0264-410X(15)01333.
    PubMed     Text format     Abstract available


  52. SAUERWEIN RW, Bousema T
    Transmission blocking malaria vaccines: Assays and candidates in clinical development.
    Vaccine. 2015 Sep 24. pii: S0264-410X(15)01213.
    PubMed     Text format     Abstract available


    August 2015
  53. HOFFMAN SL, Vekemans J, Richie TL, Duffy PE, et al
    The march toward malaria vaccines.
    Vaccine. 2015 Aug 28. pii: S0264-410X(15)01070.
    PubMed     Text format     Abstract available


  54. KUMAR R, Ray PC, Datta D, Bansal GP, et al
    Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.
    Vaccine. 2015 Aug 20. pii: S0264-410X(15)01147.
    PubMed     Text format     Abstract available


  55. DUNACHIE S, Hill AV, Fletcher HA
    Profiling the host response to malaria vaccination and malaria challenge.
    Vaccine. 2015 Aug 6. pii: S0264-410X(15)01116.
    PubMed     Text format     Abstract available


  56. DUNACHIE S, Berthoud T, Hill AV, Fletcher HA, et al
    Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model.
    Vaccine. 2015 Aug 6. pii: S0264-410X(15)01065.
    PubMed     Text format     Abstract available


    July 2015
  57. HO MM, Baca-Estrada M, Conrad C, Karikari-Boateng E, et al
    Implementation workshop of WHO guidelines on evaluation of malaria vaccines: Current regulatory concepts and issues related to vaccine quality, Pretoria, South Africa 07 Nov 2014.
    Vaccine. 2015 Jul 9. pii: S0264-410X(15)00924.
    PubMed     Text format     Abstract available


    April 2015
  58. TACHIBANA M, Suwanabun N, Kaneko O, Iriko H, et al
    Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization.
    Vaccine. 2015;33:1901-8.
    PubMed     Text format     Abstract available


  59. SINGH SK, Roeffen W, Andersen G, Bousema T, et al
    A Plasmodium falciparum 48/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies.
    Vaccine. 2015;33:1981-6.
    PubMed     Text format     Abstract available


    January 2015
  60. SALA KA, Nishiura H, Upton LM, Zakutansky SE, et al
    The Plasmodium berghei sexual stage antigen PSOP12 induces anti-malarial transmission blocking immunity both in vivo and in vitro.
    Vaccine. 2015;33:437-45.
    PubMed     Text format     Abstract available


    December 2014
  61. LULE SA, Mawa PA, Nkurunungi G, Nampijja M, et al
    Factors associated with tuberculosis infection, and with anti-mycobacterial immune responses, among five year olds BCG-immunised at birth in Entebbe, Uganda.
    Vaccine. 2014 Dec 18. pii: S0264-410X(14)01643.
    PubMed     Text format     Abstract available


    July 2014
  62. UMEH R, Oguche S, Oguonu T, Pitmang S, et al
    Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: A randomized, double-blind, lot-to-lot consistency trial.
    Vaccine. 2014 Jul 28. pii: S0264-410X(14)01019.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malaria is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: